https://www.selleckchem.com/products/loxo-292.html
The ORR was 11.1% (95% CI 1.4-34.7%) and the DCR was 77.8% (95% CI 52.4-93.6%). The median PFS was 3.5 (95% CI 1.9-5.1) months, the median OS was 4.7 (95% CI 2.0-7.3) months, and the median TTP was 4.2 (95% CI 0.562-7.838) months. All 20 (100%) patients had AEs, 17 (85%) had apatinib treatment-emergent AEs (TEAEs), and 18 (90%) had chemotherapy TEAEs. The main grade 3-4 TEAEs were neutropenia, leukopenia, hypertension, and anemia. This preliminary study suggests that apatinib combined with PTX or POF might be effective and tolerable in
Like
Comment
Share
